About Alpha-9 Oncology
Alpha-9 Oncology is a Healthcare company based in Boston (United States) founded in 2018. Radiopharmaceuticals for cancer treatment are developed using peptide-based technologies. Alpha-9 Oncology has raised $261 million across 3 funding rounds from investors including Lightspeed Venture Partners, Janus Henderson Investors and RA Capital. Its chief executive, as recorded, is David Hirsch. Alpha-9 Oncology offers products and services including Radiopharmaceuticals. Its focus areas include Life Sciences, Oncology, Drugs and Diversified. Its legal entity is Alpha-9 Oncology, Inc. Its competitors include SOFIE, Mariana Oncology and Lantheus; 2 of its 3 listed competitors have raised funding.
Company details
Alpha-9 Oncology was founded in 2018 in Boston, United States, within the oncology sector. Radiopharmaceuticals are developed to target cancer cells through radiotherapeutic design. A range of technologies for peptide-based compounds is applied to deliver radiation precisely. Operations focus on advancing treatments for individuals affected by cancer, with emphasis on innovative delivery methods in the radiopharmaceutical field.
- Headquarters Boston, United States
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website a9oncology.com
- Social LinkedIn
- Legal Name Alpha-9 Oncology, Inc.
- Total Equity Funding$261M (USD)
in 3 rounds
- Latest Funding Round$175M (USD), Series C
Oct 2024
- InvestorsLightspeed Venture Partners
& 14 more
Products & Services of Alpha-9 Oncology
Alpha-9 Oncology offers a comprehensive portfolio of products and services, including Radiopharmaceuticals.
Targeted molecules for precise cancer cell treatment using radioisotopes
Funding Insights of Alpha-9 Oncology
Alpha-9 Oncology has successfully raised a total of $261M across 3 strategic funding rounds. The most recent funding activity was a Series C round of $175 million completed in October 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $261M
- Total Rounds 3
- Last Round Series C — $175M
- First Round $11M
(Apr 2021)
- Investors Count 15
All 3 funding rounds of Alpha-9 Oncology with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2024 | $175M | Series C | – | Lightspeed Venture Partners, Ascenta Capital | |
| Dec 2022 | $75M | Series B | – | Nextech Invest | |
| Apr 2021 | $11M | Series A | – | Longitude Capital |
15 investors in total: 15 institutional.
Investors in Alpha-9 Oncology
Alpha-9 Oncology has secured backing from 15 investors, including venture fund and institutional investors. Prominent investors backing the company include Lightspeed Venture Partners, Janus Henderson Investors and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital investing in innovative companies across global sectors is undertaken by Lightspeed Venture Partners. | 1997 | lsvp.com | Menlo Park, United States | |
Ascenta Capital is focused on biopharma investment and growth. | ascentacap.com | |||
Investment and transformation services for entrepreneurs in technology and finance sectors. | generalcatalyst.com | |||
Multiple sectors are targeted for venture capital investments. | 1934 | janushenderson.com | London, United Kingdom | |
Delos Capital is engaged in private equity and financial advisory services. | deloscap.com | New York City, United States | ||
Digitalis Ventures is engaged in health-focused investments. | digitalisventures.com | New York, United States | ||
Lumira Ventures is engaged in life sciences venture capital investment. | lumiraventures.com | Toronto, Canada | ||
Healthcare investment firm focused on novel therapeutics development. | frazierls.com | Palo Alto, United States | ||
Private equity firm focused on life science sector | longitudecapital.com | Menlo Park, United States | ||
PE firm investing in the US | nextechinvest.com | Zurich, Switzerland |
Investor details for Alpha-9 Oncology
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Alpha-9 Oncology
5 people are tracked at Alpha-9 Oncology (5 in leadership).
| Name | Role | Group |
|---|---|---|
David Hirsch | CEO | Leadership |
Katherine Li | Executive Director Business Development | Leadership |
Stephen Mitchener | Chief Business Officer | Leadership |
Alison Fleming | COO | Leadership |
Megan Bumgarner | Director, Tx Pharmaceutical Development | Leadership |
Complete people profiles for Alpha-9 Oncology
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of Alpha-9 Oncology
3 dated milestones of Alpha-9 Oncology across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Alpha-9 Oncology is founded.
- Funding First funding round of $11.0M.
- Funding Latest funding round, Series C, of $175.0M.
Competitors of Alpha-9 Oncology
Alpha-9 Oncology has 3 listed competitors in our database, 2 of them funded. They include SOFIE, Mariana Oncology and Lantheus.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| sofie.com | 2008 | Culver, United States | $43.1M | 546 | Developer of molecular imaging systems and radio-pharmaceuticals | |
| marianaoncology.com | 2020 | Watertown, United States | $250M | 41 | Targeted radiopharmaceuticals for solid tumors are developed and pioneered. | |
| lantheus.com | 2008 | Billerica, United States | 834 | Developer of diagnostic imaging agents and targeted therapeutics |
Detailed competitors of Alpha-9 Oncology
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Alpha-9 Oncology
The website of Alpha-9 Oncology (a9oncology.com) receives about 4K visits a month.
- Monthly visits4K
▼ 3.9% vs previous month
Top companies in Oncology
3 companies that operate in the same segment as Alpha-9 Oncology (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Alpha-9 Oncology
Complete news archive for Alpha-9 Oncology
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Alpha-9 Oncology
Alpha-9 Oncology was founded in 2018 and raised its 1st funding round 3 years after it was founded.
Alpha-9 Oncology is headquartered in Boston, United States. It is registered at Boston, Massachusetts, United States.
David Hirsch is the CEO of Alpha-9 Oncology, as recorded in our data.
Alpha-9 Oncology is a funded company, having raised a total of $261M across 3 funding rounds to date. The company's 1st funding round was a Series A of $11M, raised on Apr 2021.
Alpha-9 Oncology was founded in 2018 in Boston, United States, within the oncology sector. Radiopharmaceuticals are developed to target cancer cells through radiotherapeutic design. A range of technologies for peptide-based compounds is applied to deliver radiation precisely. Operations focus on advancing treatments for individuals affected by cancer, with emphasis on innovative delivery methods in the radiopharmaceutical field.
Alpha-9 Oncology's top competitors include SOFIE, Mariana Oncology and Lantheus.
Alpha-9 Oncology offers Radiopharmaceuticals.
Alpha-9 Oncology has 15 investors. Key investors include Lightspeed Venture Partners, Janus Henderson Investors, RA Capital, Ascenta Capital, and General Catalyst.
Alpha-9 Oncology operates through Alpha-9 Oncology, Inc..